{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:25:39Z","timestamp":1782127539509,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer HealthCare LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.anai.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T12:00:29Z","timestamp":1620993629000},"page":"342-348.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparative nasal airflow with loratadine-pseudoephedrine and fluticasone nasal spray for allergic rhinitis"],"prefix":"10.1016","volume":"127","author":[{"given":"Charlene C.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Romaikin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Steacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.anai.2021.05.001_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2017.08.012","article-title":"Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update","volume":"119","author":"Dykewicz","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2021.05.001_bib0002","series-title":"White Book on Allergy: Update 2013","author":"Pawankar","year":"2013"},{"issue":"5","key":"10.1016\/j.anai.2021.05.001_bib0003","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMcp1412282","article-title":"Allergic rhinitis","volume":"372","author":"Wheatley","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2021.05.001_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-8-7","article-title":"The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients","volume":"8","author":"Keith","year":"2012","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"9809","key":"10.1016\/j.anai.2021.05.001_bib0005","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(11)60130-X","article-title":"Allergic rhinitis","volume":"378","author":"Greiner","year":"2011","journal-title":"Lancet"},{"issue":"suppl 5","key":"10.1016\/j.anai.2021.05.001_bib0006","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.jaci.2004.08.043","article-title":"Inflammatory mediators in allergic rhinitis","volume":"114","author":"Gelfand","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"3 Pt 2","key":"10.1016\/j.anai.2021.05.001_bib0007","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1016\/S0091-6749(99)70216-2","article-title":"Clinical manifestations of the release of histamine and other inflammatory mediators","volume":"103","author":"Naclerio","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.05.001_bib0008","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0091-6749(05)80223-4","article-title":"The role of histamine in allergic diseases","volume":"86","author":"White","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.05.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2016.10.010","article-title":"Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US patients","volume":"5","author":"Meltzer","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2021.05.001_bib0010","unstructured":"US National Library of Medicine. Label: Claritin-D 12 hour\u2014loratadine and pseudoephedrine sulfate tablet, extended release. DailyMed. Available at:https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a7125705-01ff-4418-8c53-9209c2bbb484. Accessed October 20, 2020."},{"key":"10.1016\/j.anai.2021.05.001_bib0011","unstructured":"US National Library of Medicine. Label: Flonase allergy relief\u2014fluticasone propionate spray, metered. DailyMed. Available at:https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d. Accessed October 20, 2020."},{"issue":"1","key":"10.1016\/j.anai.2021.05.001_bib0012","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1081-1206(10)61909-6","article-title":"Onset of action, efficacy and safety of fexofenadine 60 mg\/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit","volume":"89","author":"Berkowitz","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.anai.2021.05.001_bib0013","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.clinthera.2006.10.023","volume":"28","author":"Berkowitz","year":"2006","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.anai.2021.05.001_bib0014","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1081-1206(10)62280-6","article-title":"Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge","volume":"84","author":"Georgitis","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.05.001_bib0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1067\/mai.2000.104550","article-title":"Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model","volume":"105","author":"Day","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.05.001_bib0016","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1081-1206(10)63300-5","article-title":"Onset of therapeutic effect of fluticasone propionate aqueous nasal spray","volume":"86","author":"Meltzer","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2021.05.001_bib0017","unstructured":"GlaxoSmithKline. Flonase (fluticasone propionate) [package insert]. US Food and Drug Administration. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020121s045lbl.pdf. Accessed May 30, 2020."},{"key":"10.1016\/j.anai.2021.05.001_bib0018","series-title":"Pharmacotherapy: A Pathophysiologic Approach","article-title":"Allergic rhinitis","author":"May","year":"2020"},{"issue":"5","key":"10.1016\/j.anai.2021.05.001_bib0019","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.anai.2013.07.019","article-title":"Environmental exposure unit: a sensitive, specific, and reproducible methodology for allergen challenge","volume":"111","author":"Ellis","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.05.001_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11882-015-0514-4","article-title":"Controlled allergen challenge facilities and their unique contributions to allergic rhinitis research","volume":"15","author":"North","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.anai.2021.05.001_bib0021","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry allergic rhinitis: developing drug products for treatment. Available at:https:\/\/www.fda.gov\/media\/71158\/download. Accessed May 29, 2020."},{"key":"10.1016\/j.anai.2021.05.001_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13601-017-0169-4","article-title":"Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA2LEN study","volume":"7","author":"Boelke","year":"2017","journal-title":"Clin Transl Allergy"},{"issue":"12","key":"10.1016\/j.anai.2021.05.001_bib0023","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/lary.24810","article-title":"The clinical value of peak nasal inspiratory flow, peak oral inspiratory flow, and the nasal patency index","volume":"124","author":"Tsounis","year":"2014","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.anai.2021.05.001_bib0024","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/all.12778","article-title":"Measurements of nasal airflow and patency: a critical review with emphasis on the use of peak nasal inspiratory flow in daily practice","volume":"71","author":"Ottaviano","year":"2016","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2021.05.001_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2273.1999.00208.x","article-title":"The effects of oral pseudoephedrine on nasal patency in the common cold: a double-blind single-dose placebo-controlled trial","volume":"24","author":"Taverner","year":"1999","journal-title":"Clin Otolaryngol Allied Sci"},{"issue":"2","key":"10.1016\/j.anai.2021.05.001_bib0026","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S1081-1206(10)60240-2","article-title":"A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienne Challenge Chamber","volume":"102","author":"Horak","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.05.001_bib0027","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/194589240501900105","article-title":"Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold","volume":"19","author":"Eccles","year":"2005","journal-title":"Am J Rhinol"},{"issue":"2","key":"10.1016\/j.anai.2021.05.001_bib0028","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cpdd.39","article-title":"Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection","volume":"3","author":"Eccles","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"10.1016\/j.anai.2021.05.001_bib0029","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1185\/030079906X154105","article-title":"Efficacy of a paracetamol\u2013pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection","volume":"22","author":"Eccles","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.anai.2021.05.001_bib0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1081-1206(10)61894-7","article-title":"A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis","volume":"88","author":"Bende","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.05.001_bib0031","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0091-6749(96)80065-0","article-title":"Fluticasone proprionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis","volume":"97","author":"Bronsky","year":"1996","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.05.001_bib0032","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.anai.2016.07.018","article-title":"Efficacy of the novel nasal steroid S0597 tested in an environmental exposure unit","volume":"117","author":"Ellis","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.05.001_bib0033","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2500\/aap.2016.37.3950","article-title":"A phase IV, single-center, crossover evaluation of the efficacy of an external nasal dilator strip in children with nasal congestion","volume":"37","author":"Johnson","year":"2016","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"10.1016\/j.anai.2021.05.001_bib0034","doi-asserted-by":"crossref","first-page":"AB152","DOI":"10.1016\/j.jaci.2019.12.391","article-title":"The correlation between objective peak nasal inspiratory flow measurements (PNIF) and subjective allergy symptom assessments in the environmental exposure unit (EEU) [abstract only]","volume":"145","author":"Ng","year":"2020","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621003483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621003483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:27:15Z","timestamp":1761053235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120621003483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1081120621003483"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2021.05.001","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative nasal airflow with loratadine-pseudoephedrine and fluticasone nasal spray for allergic rhinitis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}